How might HPV testing be integrated into cervical screening?

The Lancet Oncology

Volumn 13, Issue 1, 2012, Pages 8-10

  Katki, Hormuzd A ^a   Wentzensen, Nicolas ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GRADING; CANCER GROWTH; CANCER PREVENTION; CANCER RISK; CLINICAL PRACTICE; CLINICAL PROTOCOL; FEMALE; HEALTH PROGRAM; HUMAN; INTERMETHOD COMPARISON; LETTER; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PRECANCER; PRIORITY JOURNAL; SCREENING TEST; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DIAGNOSIS; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84855329538     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70334-5     Document Type: Letter

References (11)

1. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2011, published online Dec 15. 10.1016/S1470-2045(11)70296-0.
2. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008, 337:a1754.
3. Kjaer SK, Frederiksen K, Munk C, Iftner T Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010, 102:1478-1488.
4. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007, 357:1579-1588.
5. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010, 11:249-257. on behalf of the New Technologies for Cervical Cancer screening (NTCC) Working Group.
6. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009, 360:1385-1394.
7. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011, 12:663-672.
8. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011, 103:368-383.
9. Katki HA, Kinney WK, Fetterman B, et al. Premature conclusions on HPV-only testing-Authors' reply. Lancet Oncol 2011, 12:993.
10. Castle PE, Katki HA Benefits and risks of HPV testing in cervical cancer screening. Lancet Oncol 2010, 11:214-215.
11. Katki HA, Wacholder S, Solomon D, Castle PE, Schiffman M Risk estimation for the next generation of prevention programmes for cervical cancer. Lancet Oncol 2009, 10:1022-1023.